Relmada Therapeutics (NASDAQ:RLMD) just reported results for the fourth quarter of 2023.
- Relmada Therapeutics reported earnings per share of -84 cents. This was below the analyst estimate for EPS of -83 cents.
- The company did not report any revenue for the quarter.